


The fund aims to provide capital growth by investing in a diversified global portfolio of predominantly equities. The fund is actively managed, and is not constrained by any requirement to track indices or conform to investment fashion.
| Name | % Net Assets |
|---|---|
| Science Group | 3.7% |
| Runge | 2.6% |
| Novartis | 2.2% |
| Groupe Bruxelles Lambert | 2.2% |
| Leucadia National | 1.6% |
| Continental Building Products | 1.6% |
| Castings | 1.6% |
| ExxonMobil | 1.6% |
| Microgen | 1.6% |
| Balfour Beatty | 1.6% |
| Key | % Net Assets |
|---|---|
| 3.7% | |
| 2.6% | |
| 2.2% | |
| 2.2% | |
| 89.3% |
| Date | 16-Nov-2022 |
|---|---|
| NAV | 502.37p |
| Currency | GBP |
| Change | 502.37p |
| % | n/a |
| YTD change | 502.37p |
| YTD % | n/a |
| Fund Inception | 01/12/1999 |
|---|---|
| Fund Manager | Alex Grispos |
| TER | 1.56 (15-Mar-2013) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £100 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | -0.18 |
You are here: research